Oncology drugs

arrow back backwards u-turn turn around reverse

Ascletis slashes funds for former core programs in obesity pivot

Ascletis is increasing investment in obesity while retreating from antiviral, oncology and liver programs that were once at the heart of its strategy.

Nick Paul Taylor Mar 26, 2025 10:00am

share price stock stock price shares falling falling

Pyxis' shares fall on lukewarm early ADC results in solid tumors

Nov 21, 2024 2:30pm

AstraZeneca pays $19M for Nona's preclinical cancer antibodies

May 23, 2024 5:58am

Takeda gets crafty with molecular glue deal worth $1.2B biobucks

May 23, 2024 5:30am

FDA's Richard Pazdur explains confirmatory trial rejection, more

Apr 8, 2024 6:00am

Fosun, Treehill join forces to invest in drugs angling for US

Nov 20, 2023 6:30am